Treatment outcomes for equine osteoarthritis with mesenchymal stromal cells and hyaluronic acid.

ABSTRACT:

Background

Mesenchymal stromal cells (MSCs) are widely used to treat osteoarthritis (OA). Optimising dose, timing, and safety while comparing efficacy with standard therapies like hyaluronic acid (HA) is essential for their standardisation.

Objectives

To assess the safety and efficacy of equine umbilical cord-derived (eCB) MSCs in client-owned horses with fetlock or carpus OA.

Study design

Prospective single-blinded randomised clinical study.

Methods

Horses diagnosed with fetlock or carpus OA via intra-articular (IA) anaesthesia were randomly assigned to receive either 10 or 20 million eCB-MSCs in HA or 3 mL of HA alone (control). Subjective lameness examinations were performed at baseline, 3 weeks, and 6 weeks post-treatment. Adverse reactions were evaluated 2

SUBMITTER: Luque RM 

PROVIDER: S-EPMC12326944 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature